Sanger GJ - Search Results

1

5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.

Bermudez J, Fake CS, Joiner GF, Joiner KA, King FD, Miner WD, Sanger GJ. Bermudez J, et al. Among authors: sanger gj. J Med Chem. 1990 Jul;33(7):1924-9. doi: 10.1021/jm00169a016. J Med Chem. 1990. PMID: 2362270

2

Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets.

Bermudez J, Sanger GJ. Bermudez J, et al. Among authors: sanger gj. J Pharm Pharmacol. 1994 Jun;46(6):520-1. doi: 10.1111/j.2042-7158.1994.tb03843.x. J Pharm Pharmacol. 1994. PMID: 7932054

3

Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants.

King FD, Hadley MS, Joiner KT, Martin RT, Sanger GJ, Smith DM, Smith GE, Smith P, Turner DH, Watts EA. King FD, et al. Among authors: sanger gj. J Med Chem. 1993 Mar 19;36(6):683-9. doi: 10.1021/jm00058a004. J Med Chem. 1993. PMID: 8459397

4

Benzotriazinones as "virtual ring" mimics of o-methoxybenzamides: novel and potent 5-HT3 receptor antagonists.

King FD, Dabbs S, Bermudez J, Sanger GJ. King FD, et al. Among authors: sanger gj. J Med Chem. 1990 Nov;33(11):2942-4. doi: 10.1021/jm00173a002. J Med Chem. 1990. PMID: 2231593 No abstract available.

5

From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists.

Sanger GJ, King FD. Sanger GJ, et al. Drug Des Deliv. 1988 Dec;3(4):273-95. Drug Des Deliv. 1988. PMID: 3076395 Review.

6

N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.

Gaster LM, Joiner GF, King FD, Wyman PA, Sutton JM, Bingham S, Ellis ES, Sanger GJ, Wardle KA. Gaster LM, et al. Among authors: sanger gj. J Med Chem. 1995 Nov 24;38(24):4760-3. doi: 10.1021/jm00024a002. J Med Chem. 1995. PMID: 7490724 No abstract available.

7

The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

Bermudez J, Boyle EA, Miner WD, Sanger GJ. Bermudez J, et al. Among authors: sanger gj. Br J Cancer. 1988 Nov;58(5):644-50. doi: 10.1038/bjc.1988.277. Br J Cancer. 1988. PMID: 2851311 Free PMC article.

8

Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.

Miner WD, Sanger GJ, Turner DH. Miner WD, et al. Among authors: sanger gj. Br J Cancer. 1987 Aug;56(2):159-62. doi: 10.1038/bjc.1987.177. Br J Cancer. 1987. PMID: 3311109 Free PMC article.

9

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Miner WD, Sanger GJ. Miner WD, et al. Among authors: sanger gj. Br J Pharmacol. 1986 Jul;88(3):497-9. doi: 10.1111/j.1476-5381.1986.tb10228.x. Br J Pharmacol. 1986. PMID: 3742146 Free PMC article.

10

BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.

Blackburn TP, Baxter GS, Kennett GA, King FD, Piper DC, Sanger GJ, Thomas DR, Upton N, Wood MD. Blackburn TP, et al. Among authors: sanger gj. Psychopharmacology (Berl). 1993;110(3):257-64. doi: 10.1007/BF02251279. Psychopharmacology (Berl). 1993. PMID: 7831418

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

212 results

Search Page

Filters